RegMed Investors’ (RMi) pre-open: holding onto gains or evacuate from risk

March 21, 2022 7:23am

The good times don’t always last, build cash positions as recent highs with partial sells

Pre-open indications: 7 SELLs and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.26% (-90 points), S&P futures are DOWN -0.04% (-2 points) and NASDAQ futures are DOWN -0.15% (-21 points)

U.S. stock futures were slipping lower in pre-open trading on Monday,

European stocks were basically flat as global sentiment continues declining,

Asia-Pacific stocks were mixed, as investors reacted to the release of China’s latest benchmark lending rate going unchanged.

Henry’omics:

Last week, the three major averages notched their best week since November 2020, the S&P 500 surged 6.1%, the Dow +5.5% higher, and the Nasdaq was even higher at +8.1%.

Think of last week, “after selling off Monday, the major indexes roared higher over the four days, reclaiming key resistance levels and staging follow-through days to confirm the new uptrend.” Could we see a repeater …?

Note: Covered equities dropped – Athersys (ATHX), Caladrius Biosciences (CLBS), - both below $1.00; CEO left - ReNeuron (RENE.L), Stemline Therapeutics (STML) - acquired; added: Agenus (AGEN), AVROBIO (AVRO), Beam Therapeutics (BEAM) and Caribou Biosciences (CRBU). Back to 35 …

RegMed Investors’ (RMi) closing bell: “sector highs respond to lessened resistance motivating sentiment. Although higher volume moves the needle, I’m still advocating selling highs and building cash positions.” … https://www.regmedinvestors.com/articles/12348

Ebb and flow –

·         March – 7 negative and 7 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  28 total

Companies in my headlights – It’s your decision; I provide ideas and context:

Maintaining SELL into Strength:

Sage Therapeutics (SAGE) closed up +$0.79 to $34.69 after Thursday’s +$0.44, Wednesday’s +$2.09 and Tuesday’s +$0.66 with a positive +$0.07 or +0.20% pre-open indication.

Editas Medicine (EDIT) closed up again +$1.09 to $18.36 after Thursday’s +$1.11, Wednesday’s +$1.25, Tuesday’s +$0.83 and last Monday’s -$0.98 with a positive +$0.31 or +1.69% pre-open indication.

CRISPR Therapeutics (CRSP) closed up again +$0.43 to $67.89 after Thursday’s +$1.92, Wednesday’s +$5.50, Tuesday’s +$1.98 and last Monday’s -$3.36 with a positive +$1.11 or +1.63% pre-open indication.

Intellia Therapeutics (NTLA) closed up again +$3.28 to $72.33 after Thursday’s +$3.13, Wednesday’s +$7.65, Tuesday’s -$0.53 and last Monday’s -$2.49 to $58.80 with a positive +$1.37 or +1.89% pre-open indication.

Fate Therapeutics (FATE) closed up again +$1.68 to $37.75 after Thursday’s +$2.02, Wednesday’s +$2.74, Tuesday’s +$1.64 and last Monday’s -$3.88 with a positive +$0.08 or +0.21% pre-open indication.

BioLife Solutions (BLFS) closed up again +$1.68 to $24.61 after Thursday’s +$1.43, Wednesday’s +$0.15 with a negative -$1.24 or -5.04% pre-open indication. I still have questions surrounds WHY – Nasdaq notice of non-compliance regarding additional delay in the filing of its Annual Report on Form 10-K for the year ended December 31, 2021?

Global Blood Therapeutics (GBT) closed up again +$1.40 to $32.59 after Thursday’s +$1.06 and Wednesday’s +$1.28 with a negative -$1.62 or -4.97% pre-open indication.

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed flat at $4.47 with 26 shares traded after Thursday’s up +$0.47 with 1,737 shares traded after Wednesday’s flat with 765 shares traded, Tuesday’s -$0.30 to $4.00 with 380 shares traded, Monday’ 28 shares traded and last Friday’s +$0.39 to $4.30 with 1,602 shares traded …

• WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
• Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering …
• BSTG is NOT going ANYWHERE without a cash infusion.

The BOTTOM LINE: After a four (4) session sector rally are you as an investor willing to wait-it-out for the falling knife?

It’s coming …

This market remains at the mercy of the latest headline as war and killing news is the bane of March lifting or sinking the major indexes.

Caution is still in order. The sector should begin to struggle, with some equities slipping from highs. I say, cut or partially sell into strength without totally removing some names.

There are still plenty of hurdles i.e., as economy faces struggles, European war headlines - hopes of progress in talks between the two sides last week fading, and maybe further earnings surprises - another eight (8) are due.

I believe many of the oversold show buy signals but very likely will reverse lower.

There is no clear trend, and no reason to make any BUYS - however, the better way of saying but … short-term pops are (to me) clearly evident.

As I have stated yesterday, “bounce, baby, bounce”.

Earnings’ reporting on the horizon:

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it defines purpose that takes courage, resolve and patience to stay the course of asking the questions without response!